Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE101 in Healthy Japanese and Chinese Participants
NCT07525947Phase 1Recruiting
- Sponsor
- Jade Biosciences, Inc.
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of JADE101 (2 arms), sponsored by Jade Biosciences, Inc. Primary endpoints: Safety and tolerability, Maximum Observed Plasma Concentration and 3 more. Started May 2026; status: recruiting.
02
Drugs
JADE101
Beyond the preview
Go deeper on NCT07525947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07525947.